PureBiotic 90 vcaps

Natural Full Spectrum Probiotic Blend

This advanced probiotic formula supports a healthy digestive system and also immune function. It is ideal for individuals with poor B-vitamin production, antibiotic use, fungal infections, constipation, diarrhea, Crohn's desease and ulcerative colitis.

Retail customers: Buy 3 or more at a discounted price.

More details

Customers who bought this product also bought:

Designed for a complete intestinal repopulation of upper and lower intestines with 27 billion cultures from 13 different clinically supported strains per serving. This advanced probiotic formula is used to repopulate the intestinal bacteria in those with poor B-vitamin production, antibiotic use, fungal infections, constipation, diarrhea, GERD, IBS, Crohn’s disease, and Ulcerative colitis. It can be used to protect the gut against infections during travel and antibiotic use.  Specific special features include:

  • Saccharomyces Boulardii, which adheres to pathogens such as E.coli and Clostridium difficile to immobilize or excrete them. S. boulardii is unique non-binding beneficial yeast that does not adhere to the intestinal wall and is able to survive the gastric acidity and provides competitive growth inhibition.
  • Bifidobacterium and Lactobacillus, which are known to adhere to the intestinal epithelial cells providing a natural barrier and reducing pathogens’ adhesion ability. They are also known to increase immune function and to act as natural antibiotics to kill undesirable microbes. This formula was also designed to improve lactose intolerance and digestibility of milk products.

Standard Dosage:  Take three capsules daily in divided doses with meals.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Supplement Facts

Write your review

PureBiotic   90 vcaps

PureBiotic 90 vcaps

Natural Full Spectrum Probiotic Blend

This advanced probiotic formula supports a healthy digestive system and also immune function. It is ideal for individuals with poor B-vitamin production, antibiotic use, fungal infections, constipation, diarrhea, Crohn's desease and ulcerative colitis.

Retail customers: Buy 3 or more at a discounted price.

Write your review

  1. Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. West CE, Gothefors L, Granstrom M, Kayhty H, Hammarstrom ML, Hernell O. Pediatr Allergy Immunol. Feb 2008;19(1):53-60. Lactobacillus F19 4-19 month infants Cereal with or without LF19 Fewer days on antibiotics Higher anti-tetanus antibody titers
  2. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. Paineau D, Carcano D, Leyer G, et al. FEMS Immunol Med Microbiol. Jun 2008;53(1):107-113. Bifidobacterium lactis Bl-04 and Lactobacillus acidophilus La-14 for 3 weeks Adult pilot study cholera vaccination •Enhancement of anti-cholera IgG Abs compared to placebo after 21 days
  3. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. de Vrese M, Winkler P, Rautenberg P, et al Vaccine. Nov 10 2006;24(44-46):6670-6674. • probiotic Lactobacilli and Bifidobacterium •no effect on the incidence of common cold infections •significantly shortened duration of episodes by almost 2 days •reduced severity of symptoms •increases in cytotoxic T plus T suppressor cell counts and in T helper cell counts.
  4. Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. Arslanoglu S, Moro GE, Boehm G. J Nutr. Nov 2007;137(11):2420-2424. •Infants up to 6 months old •Fewer infection episodes •No immunological studies • Most likely effects on mucosal immune system
  5. Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Rayes N, Seehofer D, Theruvath T, et al. Am J Transplant. Jan 2005;5(1):125-130 Peri-liver transplant study •Lactic Acid Bacteria (LAB) and fiber vs. fiber •3% vs 48%, respectively infection rate •Duration of antibiotic therapy reduced
  6. Effect of Lactobacillus Gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. de Vrese M, Winkler P, Rautenberg P, et al. Clin Nutr. Aug 2005;24(4):481-491. Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 for 3 months •Lower symptom score, duration, days with fever for common cold •Increased numbers of both CD8+ and CD4+ T cells
  7. Improvement of nutritional status and incidence of infection in hospitalized, enterally fed elderly by feeding of fermented milk containing probiotic Lactobacillus johnsonii La1 (NCC533). Fukushima Y, Miyaguchi S, Yamano T, et al. Br J Nutr. Nov 2007;98(5):969-977 Fermented milk containing Lactobacillus johnsonii La1 (LC1) •Nursing home population tube fed •Decreased number of days with infection •Trend towards increased phagocytosis and decreased circulating TNF-alpha
  8. Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Ivory K, Chambers SJ, Pin C, Prieto E, Arques JL, Nicoletti C. Clin Exp Allergy. Aug 2008;38(8):1282-1289. Adults with allergic rhinitis •milk drink with or without live Lactobacillus casei Shirota for 5 months •allergen-induced IgE, IL-5, IL-6 and IFN-gamma was reduced compared to PBO
  9. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. Kukkonen K, Savilahti E, Haahtela T, et al. J Allergy Clin Immunol. Jan 2007;119(1):192-198. mixture of 4 probiotic bacterial strains along with prebiotic galacto-oligosaccharides 2-4 weeks before delivery •Reduced eczema in offspring assessed at 2 years
  10. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Furrie E, Macfarlane S, Kennedy A, et al. Gut. Feb 2005;54(2):242-249. Synbiotic (Bifidobacterium longum), and a prebiotic (Synergy 1), a preferential inulin-oligofructose growth substrate for the probiotic strain for 1 month •UC patients •Decreased sigmoidoscopy scores, IL-1, TNF-alpha, rectal inflammation, rectal epithelial defensin mRNA.
  11. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. Kekkonen RA, Lummela N, Karjalainen H, et al. World J Gastroenterol. Apr 7 2008;14(13):2029-2036 Lactobacillus rhamnosus GG, Bifidobacterium animalis ssp. lactis Bb12, or Propionibacterium freudenreichii ssp. shermanii or a placebo drink for 3 wk •Healthy adults •Decreased serum CRP in all but Bb12 compared to PBO
  12. Beneficial effects of consumption of a dairy product containing two probiotic strains, Lactobacillus coryniformis CECT5711 and Lactobacillus gasseri CECT5714 in healthy children]. Lara-Villoslada F, Sierra S, Boza J, Xaus J, Olivares M. [Nutr Hosp. Jul-Aug 2007;22(4): L. coryniformis CECT5711 and L. gasseri CECT5714 for 3 wks after run in with yogurt in children •Increased salivary IgA and fecal IgA •Decreased pathogen adhesion to intestinal mucins 
  13. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Johnston BC, Supina AL, Ospina M, Vohra S. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD004827. DOI: 10.1002/14651858.CD004827.pub2
  14. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Castagliuolo I, Riegler MF, Valenick L et al. Infect Immun. 1999; 67:302–7
  15. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Mack DR, Michail S, Wei S et al. Am J Physiol. 1999; 276:G941–50.
  16. Lactobacillus plantarum 299v reduces colonization of Clostridium difficile in critically ill patients treated with antibiotics. Klarin B, Wullt M, Palmquist I et al. Acta Anaesthesiol Scand. 2008; 52:1096–102.
  17. Effectiveness of probiotics in the treatment of irritable bowel syndrome. Wilhelm SM, Brubaker CM, Varcak EA et al. Pharmacotherapy. 2008; 28:496–505.